--Ladder Capital Keeps Quarterly Dividend at $0.23 per Class A Share, Payable Oct. 15 to Shareholders of Record as of Sept. 30-February 2024-www.financetom.com

--Ladder Capital Keeps Quarterly Dividend at $0.23 per Class A Share, Payable Oct. 15 to Shareholders of Record as of Sept. 30

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Ladder Capital Keeps Quarterly Dividend at $0.23 per Class A Share, Payable Oct. 15 to Shareholders of Record as of Sept. 30

Sep 15, 2025 6:13 PM

09:44 AM EDT, 09/15/2025 (MT Newswires) --

Price: 11.56, Change: -0.06, Percent Change: -0.52

Previous page： Market Chatter: Nvidia Says 15% US Commission on China Chip Sales Still Unclear Next page： Toronto-Dominion Bank Fiscal Q3 Adjusted Earnings, Revenue Rise

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Nvidia Says 15% US Commission on China Chip Sales Still Unclear

Aug 28, 2025

06:30 AM EDT, 08/28/2025 (MT Newswires) -- Nvidia ( NVDA ) said a proposed Trump administration plan to impose a 15% commission on its AI chip sales to China remains in early discussions and lacks any formal regulatory framework, Bloomberg reported Thursday. According to the report, the company said late Wednesday that the US government has not provided details on...

Toronto-Dominion Bank Fiscal Q3 Adjusted Earnings, Revenue Rise

Aug 28, 2025

06:32 AM EDT, 08/28/2025 (MT Newswires) -- Toronto-Dominion Bank ( MLWIQXX ) reported fiscal Q3 adjusted earnings Thursday of 2.20 Canadian dollars ($1.60) per diluted share, up from CA$2.05 a year earlier. Analysts surveyed by FactSet expected CA$2.05. Adjusted revenue for the quarter ended July 31 was CA$15.61 billion, up from CA$14.24 billion a year earlier. Analysts surveyed by FactSet...

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025

Aug 28 (Reuters) - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' ( OTLK ) experimental drug to treat a type of eye condition that causes blurred vision, the company said on Thursday. ...

Lingerie maker Victoria's Secret Q2 sales beat expectations, raises 2025 sales guidance

Aug 28, 2025

Overview * Victoria's Secret Q2 sales rise 3% to $1.459 bln, beating expectations, per LSEG data * Adjusted EPS for Q2 exceeds expectations * Company raises full-year 2025 sales guidance, indicating confidence in growth Outlook * Company raises full-year 2025 sales guidance to $6.330 bln-$6.410 bln * Victoria's Secret expects Q3 net sales of $1.390 bln-$1.420 bln * Company forecasts...